Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Clinical trial NCT06196255 · RECRUITING
Trial details
- NCT number
- NCT06196255
- Sponsor
- Xuzhou Medical University
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-25
- Primary completion
- 2027-01-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.